Administrative Core

摘要 将先进的工程工具和方法整合到免疫疗法开发项目中 提高临床前治疗开发流水线效率的潜力。开发一种强大的免疫- 工程翻译加速器(ITA)是该PPG的战略目标，与科学 项目的目标。行政核心将为此提供全面领导和行政支持 促进PPG的科学目标以及建立一个变革性的ITA的更广泛的目标。 核心将推动每周会议和半年一次的讲习班，促进PPG项目的整合， 支持从这个PPG中涌现的翻译活动，构建一个协作性和创新性的癌症 明尼苏达大学的免疫工程学社区。行政核心将由MPI领导 David Odde(生物医学工程师)、David Masopust(癌症免疫学家)和David Largespada(基因组 工程师)在Paolo Provenzano(生物医学工程师)的支持下，Ingan Stromness(癌症 免疫学家)和布兰登·莫里亚蒂(基因组工程师)。行政核心的工作将得到便利 由项目经理博·康奈利撰写。 为促进这一项目小组的广泛目标，行政核心将执行以下具体目标： 目标1-提供强有力、始终如一的领导和管理，最大限度地提高PPG的影响力。 目标2--评估和促进科学进步。 目标3-建立一个协作性、支持性和创新性的癌症免疫生物工程社区。 目标4-通过创建免疫工程翻译来支持和加速临床翻译 加速器(ITA)。

Abstract Integrating advanced engineering tools and approaches into immunotherapy development projects holds the potential to improve the efficiency of the pre-clinical therapy development pipeline. Developing a robust Immuno- engineering Translation Accelerator (ITA) is a strategic goal for this PPG that stands alongside the scientific goals of the Projects. The Administrative Core will provide overall leadership and administrative support to this PPG in furtherance of the PPG’s scientific goals as well as the broader goal to establish a transformational ITA. The Core will facilitate weekly meetings and semi-annual workshops, promote integration of the PPG projects, support translational activities that emerge from this PPG, and build a collaborative and innovative cancer immuno-engineering community at the University of Minnesota. The Administrative Core will be led by MPIs David Odde (Biomedical Engineer), David Masopust (Cancer Immunologist), and David Largaespada (Genome Engineer) with support from Paolo Provenzano (Biomedical Engineer), Ingunn Stromness (Cancer Immunologist), and Branden Moriarity (Genome Engineer). The work of the Administrative Core will be facilitated by Program Manager Bo Connelly. To facilitate the broad goals of this PPG, the administrative core will implement the following specific aims: Aim 1 – Provide strong and consistent leadership and management that maximizes PPG impact. Aim 2 – Evaluate and facilitate scientific progress. Aim 3 – Build a collaborative, supportive, and innovative cancer immune bioengineering community. Aim 4 – Support and accelerate clinical translational through the creation of an Immuno-Engineering Translation Accelerator (ITA).